A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain ...

In this week's Pharma Pulse, Europe’s drug pricing standoff intensifies, CMS moves to formalize Medicare negotiation rules, ...

More than 85% of health plan actuaries surveyed for PwC's “Medical Cost Trend: Behind the Numbers 2027” report expect ...

PwC’s Philip Sclafani discusses rising payer cost exposure, GLP-1 growth, and why pharmacy spending is outpacing medical cost trend heading into 2027. Another factor is the growing pipeline of ...

In this week's Pharma Pulse, UPS commits $48 million to cold chain infrastructure, AbbVie moves to acquire Apogee Therapeutics in a $10.9 billion deal, and more. Welcome to Pharma Pulse, a ...

As health technology assessment (HTA) requirements evolve and joint clinical assessments (JCA) reshape Europe, pharma companies face growing pressure to align evidence, access, and strategy earlier in ...

Market expansion is being fueled by high-cost specialty launches and persistent access friction, amid substantial adherence-related system costs and low first-year fill rates driven by payer ...

Cate Lockhart shares how manufacturers should communicate across mixed RWE data sources and what guardrails AI needs before payers can trust it. Transparency in how real-world evidence (RWE) is ...

Market growth is propelled by high-cost specialty therapies, payer friction, and complex access pathways, making hub and patient support infrastructure increasingly central to commercialization and ...

GEODIS validated paper-based thermal covers in 86 real-world lanes, demonstrating temperature robustness in diverse climates while targeting recyclability versus incumbent foil/aluminum solutions.

China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions. China's new pharmaceutical supply chain regulations have transformed a chronic ...